Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 38% Improvement Relative Risk Israel et al. Dutasteride for COVID-19 Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? Retrospective 39,180 patients in Israel Lower hospitalization with antiandrogens (p=0.014) Israel et al., Epidemiology and Global Health Mi.., doi:10.7554/eLife.68165 Favors dutasteride Favors control
Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population
Israel et al., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165
Israel et al., Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large.., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165
Jul 2021   Source   PDF  
  All Studies   Meta
Case control study examining medication usage with a healthcare database in Israel, showing lower risk of hospitalization with dutasteride.
risk of hospitalization, 37.7% lower, OR 0.62, p = 0.01, treatment 30 of 6,530 (0.5%) cases, 240 of 32,650 (0.7%) controls, NNT 18, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Israel et al., 27 Jul 2021, retrospective, Israel, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: RESEARCH ARTICLE Identification of drugs associated with reduced severity of COVID-19 – a casecontrol study in a large population Ariel Israel1*, Alejandro A Schäffer2, Assi Cicurel1,3, Kuoyuan Cheng2, Sanju Sinha2, Eyal Schiff4, Ilan Feldhamer1, Ameer Tal1, Gil Lavie1,5†, Eytan Ruppin2†* 1 Division of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel; 2Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, United States; 3Clalit Health Services, Southern District and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 4Sheba Medical Center, Tel-Aviv University, Ramat Gan, Israel; 5Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel Abstract *For correspondence: (AI); (ER) † These authors contributed equally to this work Competing interests: The authors declare that no competing interests exist. Funding: See page 12 Received: 07 March 2021 Preprinted: 14 October 2020 Accepted: 07 July 2021 Published: 27 July 2021 Reviewing editor: Frank L van de Veerdonk, Radboudumc Center for Infectious Diseases, Netherlands This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Background: Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted a large population study in Clalit Health Services (CHS), the largest healthcare provider in Israel, insuring over 4.7 million members. Methods: Two case-control matched cohorts were assembled to assess which medications, acquired in the last month, decreased the risk of COVID-19 hospitalization. Case patients were adults aged 18 to 95 hospitalized for COVID-19. In the first cohort, five control patients, from the general population, were matched to each case (n=6202); in the second cohort, two nonhospitalized SARS-CoV-2 positive control patients were matched to each case (n=6919). The outcome measures for a medication were: odds ratio (OR) for hospitalization, 95% confidence interval (CI), and the p-value, using Fisher’s exact test. False discovery rate was used to adjust for multiple testing. Results: Medications associated with most significantly reduced odds for COVID-19 hospitalization include: ubiquinone (OR=0.185, 95% CI [0.058 to 0.458], p<0.001), ezetimibe (OR=0.488, 95% CI [0.377 to 0.622], p<0.001), rosuvastatin (OR=0.673, 95% CI [0.596 to 0.758], p<0.001), flecainide (OR=0.301, 95% CI [0.118 to 0.641], p<0.001), and vitamin D (OR=0.869, 95% CI [0.792 to 0.954], p<0.003). Remarkably, acquisition of artificial tears, eye care wipes, and several ophthalmological products were also associated with decreased risk for hospitalization. Conclusions: Ubiquinone, ezetimibe, and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings point to a promising protective effect which should be further investigated in controlled, prospective studies. Funding: This research was supported in part by the Intramural Research Program of the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop